Report cover image

Pediatric Brain Tumors - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 40 Pages
SKU # DEL18679924

Description

Pediatric Brain Tumors - Pipeline Insight, 2024



DelveInsight’s, “Pediatric Brain Tumors – Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Pediatric Brain Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Pediatric Brain Tumors Understanding

Pediatric Brain Tumors: Overview

Pediatric brain tumors consist of a diverse group of neoplasms of the spinal cord and the brain. They are usually primary but can progress to metastatic stage as well. Primary brain tumors are pretty common in children only after leukemia. Primitive neuroectodermal tumors (PNETs), benign gliomas, and craniopharyngiomas are the major tumors affecting children. Astrocytoma is the commonest tumor of the central nervous system in children.

Symptoms

Signs and symptoms of pediatric brain tumors may depend upon the location, size, and rate of growth of the tumor. Some common symptoms associated with brain tumor in children are abrupt onset of vision-related problems, headaches which may progress to become more severe and frequent, unexplained vomiting or nausea, and feeling of increased pressure in the head. A few other symptoms may include slurred speech, fuller soft spot on the skull of babies, personality or behavioral changes, trouble walking and maintaining body balance, and trouble swallowing among others.

Diagnosis

The diagnosis of brain tumor in children is done by various techniques after a thorough physical examination is done. Imaging tests such as MRI, CT, and positron emission tomography may be done to identify the location and size of the tumor. Biopsy, precision medicine diagnosis, and tests to determine the spread of tumor may also be done.

Treatment

Treatment of pediatric brain tumors may depend upon on the size, type, location, and the age and overall health of the child. Surgery, traditional radiation therapy, radiosurgery, proton beam therapy, targeted drug therapy, chemotherapy, and further rehabilitation are treatments that may be carried out.

Pediatric Brain Tumors Emerging Drugs Chapters

This segment of the Pediatric Brain Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pediatric Brain Tumors Emerging Drugs
  • INXN 2001: ZIOPHARM Oncology
INXN 2001, also known as Ad-RTS-hIL-12 plus veledimex is being developed by ZIOPHARM ONCOLOGY for pediatric brain tumor/ diffuse intrinsic pontine glioma (DIPG). It is in the phase I/II of drug development where dose-escalation study for pediatric cases of glioma including DIPG. It is a controlled IL-12 monotherapy.
  • MTX110: Midatech Pharma
Midatech pharma’s product MTX110 is being tested for the treatment of childhood brain cancers such as DIPG as well as Medulloblastoma. The drug has received the orphan drug designation by the U.S. Food and Drug Administration for Malignant Glioma, including DIPG. It is a novel formulation of the HDAC-inhibitor panobinostat in solubilized form which is being studied in an ongoing combine Phase I and Phase II in DIPG patients.

Further product details are provided in the report……..

Pediatric Brain Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Pediatric Brain Tumors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Pediatric Brain Tumors
There are approx. 7+ key companies which are developing the therapies for Pediatric Brain Tumors. The companies which have their Pediatric Brain Tumors drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Midatech Pharma and others.

Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Pediatric Brain Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pediatric Brain Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pediatric Brain Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pediatric Brain Tumors drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pediatric Brain Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Pediatric Brain Tumors.
Pediatric Brain Tumors Report Insights
  • Pediatric Brain Tumors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Pediatric Brain Tumors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Pediatric Brain Tumors drugs?
  • How many Pediatric Brain Tumors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pediatric Brain Tumors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pediatric Brain Tumors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pediatric Brain Tumors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Midatech Pharma
  • Y-mAbs Therapeutics
  • ZIOPHARM Oncology
Key Products
  • MTX110
  • INXN 2001
  • 177Lu-omburtamab-DTPA

Table of Contents

40 Pages
Introduction
Executive Summary
Pediatric Brain Tumors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pediatric Brain Tumors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pediatric Brain Tumors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pediatric Brain Tumors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
Comparative Analysis
MTX110: Midatech Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pediatric Brain Tumors Key Companies
Pediatric Brain Tumors Key Products
Pediatric Brain Tumors- Unmet Needs
Pediatric Brain Tumors- Market Drivers and Barriers
Pediatric Brain Tumors- Future Perspectives and Conclusion
Pediatric Brain Tumors Analyst Views
Pediatric Brain Tumors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us